CN113736737B - A method for culturing primary glioma-related fibroblasts - Google Patents
A method for culturing primary glioma-related fibroblasts Download PDFInfo
- Publication number
- CN113736737B CN113736737B CN202111097340.7A CN202111097340A CN113736737B CN 113736737 B CN113736737 B CN 113736737B CN 202111097340 A CN202111097340 A CN 202111097340A CN 113736737 B CN113736737 B CN 113736737B
- Authority
- CN
- China
- Prior art keywords
- tissue
- cell
- culture
- primary
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002950 fibroblast Anatomy 0.000 title claims abstract description 42
- 208000032612 Glial tumor Diseases 0.000 title claims abstract description 23
- 206010018338 Glioma Diseases 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 21
- 238000012258 culturing Methods 0.000 title description 5
- 210000004027 cell Anatomy 0.000 claims abstract description 56
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
- 238000004113 cell culture Methods 0.000 claims abstract description 12
- 239000000243 solution Substances 0.000 claims description 29
- 239000000725 suspension Substances 0.000 claims description 19
- 230000029087 digestion Effects 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 13
- 239000001963 growth medium Substances 0.000 claims description 11
- 239000006285 cell suspension Substances 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000010494 dissociation reaction Methods 0.000 claims description 9
- 230000005593 dissociations Effects 0.000 claims description 9
- 210000003743 erythrocyte Anatomy 0.000 claims description 9
- 239000008367 deionised water Substances 0.000 claims description 7
- 229910021641 deionized water Inorganic materials 0.000 claims description 7
- 239000013049 sediment Substances 0.000 claims description 7
- 108090000526 Papain Proteins 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 229940055729 papain Drugs 0.000 claims description 6
- 235000019834 papain Nutrition 0.000 claims description 6
- 229960005322 streptomycin Drugs 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 4
- 102000001974 Hyaluronidases Human genes 0.000 claims description 4
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 229960002773 hyaluronidase Drugs 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 239000011550 stock solution Substances 0.000 claims description 4
- 239000011534 wash buffer Substances 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 2
- 238000007664 blowing Methods 0.000 claims 4
- 238000005406 washing Methods 0.000 claims 3
- 102000053602 DNA Human genes 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 108010019160 Pancreatin Proteins 0.000 claims 1
- 239000012930 cell culture fluid Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 229940055695 pancreatin Drugs 0.000 claims 1
- 235000011837 pasties Nutrition 0.000 claims 1
- 238000011176 pooling Methods 0.000 claims 1
- 238000010079 rubber tapping Methods 0.000 claims 1
- 238000011146 sterile filtration Methods 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 238000012136 culture method Methods 0.000 abstract description 9
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 4
- 239000011324 bead Substances 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000000746 purification Methods 0.000 abstract description 3
- 230000021164 cell adhesion Effects 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 238000011109 contamination Methods 0.000 abstract 1
- 239000006143 cell culture medium Substances 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 9
- 230000002255 enzymatic effect Effects 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000006481 glucose medium Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000008004 cell lysis buffer Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 208000002854 epidermolysis bullosa simplex superficialis Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000007983 brain glioma Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004182 chemical digestion Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
一种原代胶质瘤相关成纤维细胞培养方法,通过创新性联合使用细胞差异贴壁法、细胞营养筛选法,该新式培养方法能够避免原代细胞培养过程中混杂大量非成纤维细胞所带来的细胞筛选困难。该新方法仅用容易获取的常规试剂便能达到超过传统方法的优良效果,在较短时间内实现P0代细胞完全纯化,值得推广。目前本课题组已经从46个新鲜人胶质瘤组织中培养出37例胶质瘤相关成纤维细胞,成功率高达80%。现有的快速实现肿瘤相关成纤维细胞培养的方法主要通过流式细胞分选或者磁珠分选,仪器、试剂价格昂贵,实验技术复杂,操作难度较高;而该细胞培养法的发明对于实验研究的经济性具有重要价值。
A primary glioma-related fibroblast culture method. Through the innovative combination of differential cell adhesion method and cell nutrient screening method, this new culture method can avoid the contamination of a large number of non-fibroblasts during the primary cell culture process. Cell screening is difficult. This new method can achieve superior results than traditional methods using only easily available conventional reagents, and can achieve complete purification of P0 generation cells in a relatively short period of time, which is worthy of promotion. Currently, our research group has cultured 37 cases of glioma-related fibroblasts from 46 fresh human glioma tissues, with a success rate of 80%. The existing methods for quickly cultivating tumor-related fibroblasts are mainly through flow cell sorting or magnetic bead sorting. The instruments and reagents are expensive, the experimental technology is complex, and the operation is difficult; and the invention of this cell culture method is very difficult for experiments. The economics of research are of great value.
Description
技术领域Technical field
本发明涉及细胞培养方法领域,特别涉及一种原代胶质瘤相关成纤维细胞培养方法。The present invention relates to the field of cell culture methods, and in particular to a primary glioma-related fibroblast culture method.
背景技术Background technique
原代胶质瘤相关成纤维细胞尚无有效的培养方法。There is no effective culture method for primary glioma-associated fibroblasts.
现有的培养方法之一:无菌流式细胞分选或者磁珠分选,需要昂贵仪器以及流式抗体,对实验条件、操作技术要求很高,经济型、便捷性很差。One of the existing culture methods: sterile flow cell sorting or magnetic bead sorting, requires expensive instruments and flow antibodies, has high requirements on experimental conditions and operating techniques, and is poor in economy and convenience.
若采用传统培养方法,如营养筛选法则需要等待细胞传代数代之后方能获取纯化原代成纤维细胞,大大减少成纤维细胞后续实验可利用代数;此外成纤维细胞增殖速度很慢,培养周期长。If traditional culture methods are used, such as the nutritional screening method, it is necessary to wait for several generations of cell passage before obtaining purified primary fibroblasts, which greatly reduces the number of generations of fibroblasts that can be used for subsequent experiments; in addition, the proliferation rate of fibroblasts is very slow and the culture cycle is long. .
综上述,胶质瘤相关成纤维细胞培养亟须解决培养周期长,细胞纯化困难、价格昂贵等难题。In summary, the culture of glioma-related fibroblasts urgently needs to solve the problems of long culture cycle, difficult cell purification, and high price.
发明内容Contents of the invention
为解决上述现有技术存在的问题,本发明的目的在于提供一种原代胶质瘤相关成纤维细胞培养方法。In order to solve the problems existing in the above-mentioned prior art, the purpose of the present invention is to provide a primary glioma-related fibroblast culture method.
为达到上述目的,本发明的技术方案为:In order to achieve the above objects, the technical solution of the present invention is:
一种原代胶质瘤相关成纤维细胞培养方法,包括如下步骤:A method for culturing primary glioma-related fibroblasts, including the following steps:
步骤a、洗涤组织:将肿瘤组织放置于冰面上的无菌培养皿中,取组织洗涤缓冲液清洗组织血凝块两遍;眼科剪剪碎组织块直至成为糊状;Step a. Wash the tissue: Place the tumor tissue in a sterile petri dish on ice, take tissue washing buffer to wash the tissue blood clot twice; cut the tissue block with ophthalmic scissors until it becomes paste;
步骤b、消化组织:Step b. Digest tissue:
向剪碎的组织中加入组织消化酶解液1,立即采用移液管将组织悬液转移至15ml试管后并轻柔吹打,37℃温浴5分钟,再次吹打悬液后温浴5分钟;Add tissue digestion enzyme solution 1 to the minced tissue, immediately transfer the tissue suspension to a 15ml test tube with a pipette and gently pipet, incubate at 37°C for 5 minutes, pipet the suspension again and incubate for 5 minutes;
向上述组织悬液中继续添加组织消化酶解液2继续于37℃温浴5分钟,再次吹打悬液后温浴5分钟;当组织悬液能够用1mL移液枪顺利吸取,表示消化完成;Continue to add tissue digestion enzymatic solution 2 to the above tissue suspension and continue to incubate at 37°C for 5 minutes. Pipet the suspension again and incubate for 5 minutes. When the tissue suspension can be smoothly absorbed with a 1mL pipette, the digestion is complete;
步骤c、过滤:向组织悬液中加入10mL PBS,吹匀后采用70μm细胞滤网过滤,将所获细胞悬液离心,400xg 3分钟,弃上清;Step c. Filtration: Add 10 mL PBS to the tissue suspension, blow evenly and filter through a 70 μm cell strainer. Centrifuge the obtained cell suspension at 400xg for 3 minutes and discard the supernatant;
步骤d、去除红细胞:向细胞沉渣中加入3倍于细胞沉淀体积的1x红细胞裂解液,室温静置5分钟;向细胞悬液中加入8mL PBS,离心后弃上清;Step d. Remove red blood cells: Add 1x red blood cell lysis buffer 3 times the volume of cell sedimentation to the cell sediment, and let stand at room temperature for 5 minutes; add 8 mL PBS to the cell suspension, centrifuge and discard the supernatant;
步骤e、原代成纤维细胞培养:现配肿瘤干细胞培养液10mL,取10mL原代细胞培养液1,并添加1000x EGF、1000x bFGF各10μL(终浓度20ng/ml),细胞计数,2x106个细胞加入培养液,培养24h。弃掉培养皿上清,PBS清洗并轻拍培养皿底部三遍,镜下观察细胞碎片及沉渣完全清洗干净后想培养皿内添加MSC培养基;三天后观察细胞形态以及生长情况并换液,拍照记录。Step e. Primary fibroblast culture: Prepare 10 mL of cancer stem cell culture medium, take 10 mL of primary cell culture medium 1, and add 10 μL each of 1000x EGF and 1000x bFGF (final concentration 20 ng/ml). Count the cells, 2x10 6 Cells were added to culture medium and cultured for 24 h. Discard the supernatant of the culture dish, wash with PBS and tap the bottom of the culture dish three times. Observe the cell debris and sediment under the microscope. After cleaning, add MSC culture medium to the culture dish. After three days, observe the cell morphology and growth and change the medium. Take photos and record.
步骤f、原代胶质瘤相关成纤维细胞培养及传代:当P0代细胞汇聚度为90%左右,消化酶(0.25%胰酶+EDTA)消化细胞,将细胞悬液离心3min,400xg;更换10%FBS-DMEM全培养液继续培养(1x106个细胞/75cm2)。(注意:原代细胞传代次数应少于10代,避免可能出现遗传和表型变化。)Step f. Culture and passage of primary glioma-related fibroblasts: When the confluence of P0 generation cells is about 90%, digest the cells with digestive enzymes (0.25% trypsin + EDTA), and centrifuge the cell suspension for 3 minutes at 400xg; replace Continue culturing in 10% FBS-DMEM complete culture medium (1x10 6 cells/75cm 2 ). (Note: The number of primary cell passages should be less than 10 generations to avoid possible genetic and phenotypic changes.)
进一步的,所述组织消化酶解液1为:组织解离液1.85mL+木瓜蛋白酶储备液100μL现用现加脱氧核糖核酸酶-I 50μL,-20℃保存;组织解离液:去离子水(441mL)+10x Hank’s平衡盐溶液(50mL)+D-葡萄糖溶液(300mg/mL)(9mL),-20℃保存。Further, the tissue digestion enzymatic solution 1 is: 1.85 mL of tissue dissociation solution + 100 μL of papain stock solution, 50 μL of deoxyribonuclease-I is added and stored at -20°C; tissue dissociation solution: deionized water ( 441mL) + 10x Hank's balanced salt solution (50mL) + D-glucose solution (300mg/mL) (9mL), store at -20°C.
进一步的,所述组织消化酶解液2:组织解离液(100mL)+胶原酶-I(70mg)+透明质酸酶(70mg),充分溶解后分装,-20℃保存。Further, the tissue digestion enzymatic solution 2: tissue dissociation solution (100 mL) + collagenase-I (70 mg) + hyaluronidase (70 mg), fully dissolved, aliquoted, and stored at -20°C.
进一步的,所述原代细胞培养液1:DMEM/F12(480mL)+青-链霉素(5mL)+50x B27(10mL),4℃保存。Further, the primary cell culture medium 1: DMEM/F12 (480 mL) + penicillin-streptomycin (5 mL) + 50x B27 (10 mL), stored at 4°C.
进一步的,所述原代细胞培养液2:间充质干细胞培养液,4℃保存。Further, the primary cell culture medium 2: mesenchymal stem cell culture medium, stored at 4°C.
进一步的,所述1000x b-FGF:b-FGF(50μg)+去离子水(2.5mL)+牛血清蛋白(2.5mg),无菌滤网过滤,-20℃保存。Further, the 1000x b-FGF: b-FGF (50 μg) + deionized water (2.5 mL) + bovine serum albumin (2.5 mg), filtered through a sterile filter, and stored at -20°C.
进一步的,所述10%FBS-DMEM:FBS(50mL)+DMEM(445mL)+P/S(5mL),4℃保存。Further, the 10% FBS-DMEM: FBS (50 mL) + DMEM (445 mL) + P/S (5 mL), stored at 4°C.
相对于现有技术,本发明的有益效果为:Compared with the existing technology, the beneficial effects of the present invention are:
1、原理创新:通过创新性联合使用细胞差异贴壁法、细胞营养筛选法,该新式培养方法能够避免原代细胞培养过程中混杂大量非成纤维细胞所带来的细胞筛选困难。1. Principle innovation: Through the innovative combination of differential cell adhesion method and cell nutrient screening method, this new culture method can avoid the difficulty of cell selection caused by mixing a large number of non-fibroblasts in the primary cell culture process.
2、便捷:该新方法仅用容易获取的常规试剂便能达到超过传统方法的优良效果,在较短时间内实现P0代细胞完全纯化,值得推广。2. Convenience: This new method can achieve superior results than traditional methods by using only easily available conventional reagents, and can achieve complete purification of P0 generation cells in a relatively short period of time, which is worthy of promotion.
3、高效:目前本课题组已经从46个新鲜人胶质瘤组织中培养出37例胶质瘤相关成纤维细胞,成功率高达80%。3. High efficiency: Currently, our research group has cultured 37 cases of glioma-related fibroblasts from 46 fresh human glioma tissues, with a success rate of 80%.
4、经济:现有的快速实现肿瘤相关成纤维细胞培养的方法主要通过流式细胞分选或者磁珠分选,仪器、试剂价格昂贵,实验技术复杂,操作难度较高;而该细胞培养法的发明对于实验研究的经济性具有重要价值。4. Economical: The existing methods for quickly cultivating tumor-related fibroblasts mainly use flow cell sorting or magnetic bead sorting. The instruments and reagents are expensive, the experimental technology is complex, and the operation is difficult; and this cell culture method The invention is of great value to the economy of experimental research.
附图说明Description of the drawings
图1为原代胶质瘤相关成纤维细胞培养流程图。Figure 1 is a flow chart of primary glioma-related fibroblast culture.
图2为原代胶质瘤相关成纤维细胞光镜形态图。Figure 2 shows the light microscope morphology of primary glioma-related fibroblasts.
图3为成纤维细胞免疫荧光染色图:FAP(绿色),Fibronectin(红色)。Figure 3 shows the immunofluorescence staining of fibroblasts: FAP (green), Fibronectin (red).
图4成纤维细胞特征性标记物αSMA在胶质瘤相关成纤维细胞中高表达。Figure 4 αSMA, a characteristic marker of fibroblasts, is highly expressed in glioma-related fibroblasts.
具体实施方式Detailed ways
下面结合附图(图1-4)和具体实施方式对本发明技术方案做进一步详细描述:The technical solution of the present invention will be further described in detail below in conjunction with the accompanying drawings (Figures 1-4) and specific implementation modes:
一、器械与试剂1. Instruments and reagents
冰盒、碎冰块、眼科剪、眼科镊、6cm细胞培养皿、10cm细胞培养皿、封口膜、15mL离心管、50mL离心管、0.22μM无菌滤网、恒温水浴锅、高速离心机、移液管、Eppendorf移液枪、Thermo细胞移液器Ice box, crushed ice, ophthalmic scissors, ophthalmic tweezers, 6cm cell culture dish, 10cm cell culture dish, sealing film, 15mL centrifuge tube, 50mL centrifuge tube, 0.22μM sterile filter, constant temperature water bath, high-speed centrifuge, transfer Liquid tubes, Eppendorf pipettes, Thermo cell pipettes
1、试剂1. Reagents
磷酸盐缓冲盐溶液(PBS)、青-链霉素、木瓜蛋白酶、透明质酸酶、胶原酶-I、胰酶、MSC培养液、DMEM/F12培养液、碱性成纤维细胞生长因子(bFGF)、表皮细胞生长因子(EGF)、B-12、胎牛血清(FBS)、高糖培养基(DMEM)、10x红细胞裂解液、去离子水(UP-H2O)、牛血清白蛋白(BSA)、D-葡萄糖、EBSS、脱氧核糖核酸酶-IPhosphate buffered saline (PBS), penicillin-streptomycin, papain, hyaluronidase, collagenase-I, trypsin, MSC culture medium, DMEM/F12 culture medium, basic fibroblast growth factor (bFGF ), epidermal growth factor (EGF), B-12, fetal bovine serum (FBS), high glucose medium (DMEM), 10x red blood cell lysate, deionized water (UP-H 2 O), bovine serum albumin ( BSA), D-glucose, EBSS, deoxyribonuclease-I
2、工作液配置2. Working fluid configuration
a、新鲜肿瘤组织保存液:1%青霉素-链霉素(5mL)+99%磷酸盐缓冲盐溶液(495mL)。a. Fresh tumor tissue preservation solution: 1% penicillin-streptomycin (5mL) + 99% phosphate buffered saline solution (495mL).
b、组织洗涤缓冲液:磷酸盐缓冲盐溶液(450mL)+牛血清白蛋白(5g)+青霉素-链霉素(5mL),0.22μM无菌滤网过滤,4℃保存。b. Tissue washing buffer: phosphate buffered saline solution (450mL) + bovine serum albumin (5g) + penicillin-streptomycin (5mL), filtered through a 0.22μM sterile filter, and stored at 4°C.
c、组织解离液:去离子水(441mL)+10x Hank’s平衡盐溶液(50mL)+D-glucose溶液(300mg/mL)(9mL),-20℃保存。c. Tissue dissociation solution: deionized water (441mL) + 10x Hank’s balanced salt solution (50mL) + D-glucose solution (300mg/mL) (9mL), stored at -20°C.
d、木瓜蛋白酶储备液:木瓜蛋白酶(20mg)+EBSS(1mL),0.22μM无菌滤网过滤,4℃保存。d. Papain stock solution: papain (20 mg) + EBSS (1 mL), filtered through a 0.22 μM sterile filter, and stored at 4°C.
e、组织消化酶解液1:组织解离液(1.85mL)+木瓜蛋白酶储备液(100μL现用现加)+脱氧核糖核酸酶-I(50μL),-20℃保存。e. Tissue digestion enzymatic solution 1: tissue dissociation solution (1.85 mL) + papain stock solution (100 μL ready for use) + deoxyribonuclease-I (50 μL), stored at -20°C.
f、组织消化酶解液2:组织解离液(100mL)+胶原酶-I(70mg)+透明质酸酶(70mg),充分溶解后分装,-20℃保存。f. Tissue digestion enzymatic solution 2: Tissue dissociation solution (100mL) + Collagenase-I (70mg) + Hyaluronidase (70mg). After fully dissolving, aliquot and store at -20°C.
g、1x红细胞裂解液:10x红细胞裂解液(10mL)+无菌蒸馏水(90mL)。g. 1x red blood cell lysis solution: 10x red blood cell lysis solution (10mL) + sterile distilled water (90mL).
h、原代细胞培养液1:96%DMEM/F12培养基(480mL)+1%P/S(5mL)+2%B27(50x)(10mL),4℃保存。h. Primary cell culture medium 1: 96% DMEM/F12 medium (480 mL) + 1% P/S (5 mL) + 2% B27 (50x) (10 mL), stored at 4°C.
i、原代细胞培养液2:间充质干细胞培养液,4℃保存。i. Primary cell culture medium 2: mesenchymal stem cell culture medium, stored at 4°C.
j、1000x碱性成纤维细胞生长因子:b-FGF(50μg)+去离子水(2.5mL)+牛血清白蛋白(2.5mg),无菌滤网过滤,-20℃保存。j. 1000x basic fibroblast growth factor: b-FGF (50 μg) + deionized water (2.5 mL) + bovine serum albumin (2.5 mg), filtered through a sterile filter, and stored at -20°C.
k、1000x表皮细胞生长因子(EGF):,无菌滤网过滤,-20℃保存。k. 1000x epidermal growth factor (EGF): filtered through a sterile filter and stored at -20°C.
l、10%胎牛血清(FBS)-高糖培养基(DMEM):10%胎牛血清(50mL)+89%高糖培养基(445mL)+1%青霉素-链霉素(5mL),4℃保存。l. 10% fetal bovine serum (FBS)-high glucose medium (DMEM): 10% fetal bovine serum (50mL) + 89% high glucose medium (445mL) + 1% penicillin-streptomycin (5mL), 4 Store at ℃.
二、操作步骤2. Operation steps
a、洗涤组织:将肿瘤组织放置于冰面上的无菌6cm培养皿中,取组织洗涤缓冲液清洗组织血凝块两遍;眼科剪剪碎组织块直至成为糊状。a. Wash the tissue: Place the tumor tissue in a sterile 6cm petri dish on ice, take tissue washing buffer to wash the tissue blood clot twice; cut the tissue block with ophthalmic scissors until it becomes paste.
b、消化组织:b. Digestive tissue:
向剪碎的组织中加入组织消化酶解液1,采用移液管将组织悬液转移至15ml试管后并轻柔吹打,37℃温浴5分钟,再次吹打悬液后温浴5分钟;Add tissue digestion enzyme hydrolyzate 1 to the minced tissue, transfer the tissue suspension to a 15ml test tube with a pipette and pipe gently, incubate at 37°C for 5 minutes, pipet the suspension again and incubate for 5 minutes;
向上述组织悬液中继续添加组织消化酶解液2重悬组织,37℃温浴5分钟,再次吹打悬液后温浴5分钟;当组织悬液能够用1mL移液枪顺利吸取,表示消化完成。Continue to add tissue digestion enzymatic solution 2 to the above tissue suspension to resuspend the tissue, incubate at 37°C for 5 minutes, pipet the suspension again and incubate for 5 minutes; when the tissue suspension can be smoothly absorbed with a 1mL pipette, the digestion is complete.
c、过滤:向组织悬液中加入10mL PBS,吹匀后采用70μM细胞滤网过滤,将所获细胞悬液离心,400xg 3分钟,弃上清。c. Filtration: Add 10 mL of PBS to the tissue suspension, blow evenly and filter with a 70 μM cell strainer. Centrifuge the obtained cell suspension at 400xg for 3 minutes and discard the supernatant.
d、去除红细胞:向细胞沉渣中加入1x红细胞裂解液(3倍于细胞沉淀体积),室温静置5分钟;向细胞悬液中加入8mL PBS,离心后弃上清。d. Remove red blood cells: Add 1x red blood cell lysis buffer (3 times the cell sedimentation volume) to the cell sediment and let it stand at room temperature for 5 minutes; add 8mL PBS to the cell suspension, centrifuge and discard the supernatant.
e、原代成纤维细胞培养(关键):现配肿瘤干细胞培养液10mL,取10mL原代细胞培养液1,并添加1000x EGF、1000x bFGF各10μL(终浓度20ng/ml),细胞计数,2x106个细胞加入培养液,培养24h。弃掉培养皿上清,PBS清洗并轻拍培养皿底部三遍,镜下观察细胞碎片及沉渣完全清洗干净后想培养皿内添加MSC培养基;三天后观察细胞形态以及生长情况并换液,拍照记录。e. Primary fibroblast culture (key): Now prepare 10 mL of cancer stem cell culture medium, take 10 mL of primary cell culture medium 1, and add 10 μL each of 1000x EGF and 1000x bFGF (final concentration 20 ng/ml), and count the cells, 2x10 6 cells were added to the culture medium and cultured for 24 hours. Discard the supernatant of the culture dish, wash with PBS and tap the bottom of the culture dish three times. Observe the cell debris and sediment under the microscope. After cleaning, add MSC culture medium to the culture dish. After three days, observe the cell morphology and growth and change the medium. Take photos and record.
f、原代胶质瘤相关成纤维细胞培养及传代:当P0代细胞汇聚度为90%左右,消化酶(0.25%胰酶+EDTA)消化细胞,将细胞悬液离心3min,400xg;更换10%FBS-DMEM全培养液继续培养(1x106个细胞/75cm2)。(注意:原代细胞传代次数应少于10代,避免可能出现遗传和表型变化。)f. Culture and passage of primary glioma-related fibroblasts: When the confluence of P0 generation cells is about 90%, digest the cells with digestive enzymes (0.25% trypsin + EDTA), and centrifuge the cell suspension for 3 minutes at 400xg; replace 10 Continue culturing in %FBS-DMEM complete culture medium (1x10 6 cells/75cm 2 ). (Note: The number of primary cell passages should be less than 10 generations to avoid possible genetic and phenotypic changes.)
以上细胞培养操作流程见图1:获取新鲜人脑胶质瘤组织,分别经过物理剪切、化学消化获取单细胞悬液;进而采用全新的原代胶质瘤相关成纤维细胞培养方式:先用肿瘤干细胞培养液悬浮培养原代细胞(筛选贴壁能力强的成纤维细胞),24小时后去除上清中未贴壁细胞后更换MSC培养液继续培养。The above cell culture operation process is shown in Figure 1: fresh human brain glioma tissue is obtained, and single cell suspension is obtained through physical shearing and chemical digestion respectively; then a new primary glioma-related fibroblast culture method is used: first The primary cells were cultured in suspension in the cancer stem cell culture medium (to select fibroblasts with strong adhesion ability). After 24 hours, the non-adherent cells in the supernatant were removed and the MSC culture medium was replaced to continue culturing.
如图2所示,对于成功培养的原代细胞,其细胞形态与肿瘤相关成纤维细胞相似,但与胶质瘤细胞形态差异很大;此外细胞培养效率很高,在第0代第15天左右原代成纤维细胞汇聚度能达到90%,且细胞形态均一,几乎无其它非成纤维细胞存在。As shown in Figure 2, for successfully cultured primary cells, their cell morphology is similar to tumor-associated fibroblasts, but very different from glioma cell morphology; in addition, the cell culture efficiency is very high, on day 15 of passage 0 The confluence of left and right primary fibroblasts can reach 90%, and the cell morphology is uniform, with almost no other non-fibroblasts present.
利用细胞免疫荧光检测了原代细胞是否高表达已知的肿瘤相关成纤维细胞细胞分子标记物,例如成纤维细胞激活蛋白(FAP)、纤连蛋白(Fibronectin),结果提示上述形态符合成纤维细胞特征的原代细胞均高表达成纤维细胞特异性标记物,如图3所示。说明该方法能够有效、快速培养出胶质瘤相关成纤维细胞。Cellular immunofluorescence was used to detect whether the primary cells highly expressed known tumor-associated fibroblast cell molecular markers, such as fibroblast activating protein (FAP) and fibronectin (Fibronectin). The results suggested that the above morphology was consistent with fibroblasts. The characterized primary cells all highly expressed fibroblast-specific markers, as shown in Figure 3. This shows that this method can effectively and quickly culture glioma-related fibroblasts.
最后,通过West Blot分别检测原代成纤维细胞、胶质瘤细胞系(U251)、间充质干细胞(MSC)成纤维细胞特异性标记物αSMA的表达水平,结果提示胶质瘤相关成纤维细胞高表达αSMA,这与阳性对照间充质干细胞表达情况相同,而阴性对照细胞U251则不表达αSMA,再次提示该方法培养出的原代细胞属于成纤维细胞。Finally, West Blot was used to detect the expression levels of the fibroblast-specific marker αSMA in primary fibroblasts, glioma cell lines (U251), and mesenchymal stem cells (MSC). The results suggested that glioma-associated fibroblasts αSMA is highly expressed, which is the same as the expression of positive control mesenchymal stem cells, while the negative control cell U251 does not express αSMA, again suggesting that the primary cells cultured by this method belong to fibroblasts.
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何不经过创造性劳动想到的变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应该以权利要求书所限定的保护范围为准。The above are only specific embodiments of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that are not thought of through creative efforts should be covered by the protection scope of the present invention. Therefore, the protection scope of the present invention should be subject to the protection scope defined by the claims.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111097340.7A CN113736737B (en) | 2021-09-18 | 2021-09-18 | A method for culturing primary glioma-related fibroblasts |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111097340.7A CN113736737B (en) | 2021-09-18 | 2021-09-18 | A method for culturing primary glioma-related fibroblasts |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113736737A CN113736737A (en) | 2021-12-03 |
| CN113736737B true CN113736737B (en) | 2023-09-08 |
Family
ID=78739893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111097340.7A Active CN113736737B (en) | 2021-09-18 | 2021-09-18 | A method for culturing primary glioma-related fibroblasts |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113736737B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114350601B (en) * | 2021-12-21 | 2022-12-27 | 广东省华晟生物技术有限公司 | Cherry valley duck fibroblast line and construction method and application thereof |
| CN119876035A (en) * | 2025-03-28 | 2025-04-25 | 南昌大学 | Method for constructing tumor organoid and fibroblast high-flux medicine sieve model |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109694852A (en) * | 2019-02-22 | 2019-04-30 | 武汉赛尔朗灵科技有限公司 | A kind of people's glioma primary cell and its In-vitro separation culture method and application |
| CN111876386A (en) * | 2020-08-10 | 2020-11-03 | 上海市第一人民医院 | A method for culturing breast cancer organoids and co-culturing method with tumor-associated fibroblasts |
| CN115491344A (en) * | 2022-09-16 | 2022-12-20 | 南昌大学 | A method for the isolation, purification and in vitro activation model construction of mouse primary lung fibroblasts |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150297613A1 (en) * | 2011-12-13 | 2015-10-22 | Servicio Andaluz De Salud | Use of agents that alter the peritumoral environment for the treatment of cancer |
| AU2018375151B2 (en) * | 2017-11-29 | 2025-06-26 | Spinalcyte Llc | Interaction of fibroblasts and immune cells for activation and uses thereof |
-
2021
- 2021-09-18 CN CN202111097340.7A patent/CN113736737B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109694852A (en) * | 2019-02-22 | 2019-04-30 | 武汉赛尔朗灵科技有限公司 | A kind of people's glioma primary cell and its In-vitro separation culture method and application |
| CN111876386A (en) * | 2020-08-10 | 2020-11-03 | 上海市第一人民医院 | A method for culturing breast cancer organoids and co-culturing method with tumor-associated fibroblasts |
| CN115491344A (en) * | 2022-09-16 | 2022-12-20 | 南昌大学 | A method for the isolation, purification and in vitro activation model construction of mouse primary lung fibroblasts |
Non-Patent Citations (1)
| Title |
|---|
| Carcinoma-Associated Fibroblast-Like Differentiation of Human Mesenchymal Stem Cells;Pravin J.Mishra;Cancer Research;第68卷(第11期);第4331-4339页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113736737A (en) | 2021-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114292816B (en) | Lung cancer organoid culture solution, and culture reagent combination and culture method thereof | |
| CN114317443A (en) | Breast cancer organoid culture solution, and culture reagent combination and culture method thereof | |
| CN113736737B (en) | A method for culturing primary glioma-related fibroblasts | |
| CN121136924A (en) | Mesenchymal stem cell membrane and preparation method thereof | |
| CN104480533A (en) | Placenta stem cell bank construction method and placenta tissue resuscitation method | |
| CN105543164A (en) | Primary isolated culture method for dairy cow mammary epithelial cells | |
| CN114540276A (en) | Three-dimensional culture method for in-vitro endometrial gland organs | |
| CN113462639A (en) | Method for separating fibroblasts from human induced pluripotent stem cells and application of method | |
| CN108300688A (en) | Primary hepatocyte detaches and cultural method | |
| CN115851587A (en) | Optimized culture medium, kit and culture method of human placenta-derived mesenchymal stem cells | |
| CN116836934B (en) | Osteosarcoma organoid culture solution, culture reagent combination and culture method | |
| CN107354130A (en) | A kind of intermembranous mesenchymal stem cells separation method of human placenia | |
| CN115322964B (en) | Construction method of 3D culture amniotic mesenchymal stem cell seed bank | |
| CN108865977A (en) | A kind of newborn rat skin end septal cell massive amplification method and application | |
| CN105695401B (en) | The preparation of all stem cells of a kind of umbilical artery and vein blood vessel and store method | |
| CN116836933B (en) | Liver and gall cancer organoid culture solution, culture reagent combination and culture method | |
| CN108660108A (en) | A kind of method enhancing umbilical cord mesenchymal stem cells immunoregulation capability | |
| CN111004782B (en) | Primary human intestinal cancer cell and culture method and application thereof | |
| CN114276986A (en) | A method for separating and purifying buffalo primary myoblasts and its application | |
| CN119709618B (en) | A method for sorting mature RPE cells from iPSC-differentiated cells and its application | |
| CN114058573B (en) | A culture medium containing biotin | |
| WO2022056991A1 (en) | Mesenchymal stem cells derived from umbilical cord, and preparation method therefor and use thereof | |
| CN115232792B (en) | Culture medium and culture method for pleural fluid source organoid | |
| CN111979176B (en) | Preparation method of human corneal epithelial cells, conditioned medium thereof and preparation method thereof | |
| CN113430229B (en) | Construction method of human-derived BAV-TAA disease pluripotent stem cell model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |